Kelley et al., 2019
I., Celiker, H., Donder, E., and Gunal, S
Key Research Findings CAM Assay: BPC-157 increases blood vessel formation in chorioallantoic membrane models Wound Models: Enhanced angiogenesis observed in cutaneous wound healing studies VEGF Blockade: VEGF inhibitors (bevacizumab) partially block BPC-157's healing effects, confirming VEGF involvement L-NAME Studies: NOS inhibition reduces BPC-157 efficacy, confirming NO pathway involvement Potential Applications The angiogenic mechanism suggests utility in: Chronic Wounds: Diabetic ulcers and pressure sores with impaired healing Sports Injuries: Tendon, ligament, and muscle repair Post-Surgical: Accelerating anastomotic and incisional healing Ischemic Conditions: Enhancing blood supply to poorly perfused tissues Considerations Cancer Context: Angiogenesis is a concern in malignancy
It is an abnormal condition characterized by the uneven distribution of body fat
Any use outside of formally approved clinical trials falls outside the regulatory framework that governs medicines safety in the UK, meaning that individuals who obtain and use retatrutide independently do so without the quality assurance, standardised dosing oversight, and pharmacovigilance protections afforded by licensed medicines
